CD276 and small cell lung carcinoma: Additional targets implicated in NE transformation have emerged from analyses of de novo SCLC and histologically transformed samples, including B7-H3/CD276, B7-H6, SEZ6, TROP-2, CEACAM5, and others.228–234 Therapeutic strategies targeting these molecules are diverse, including ADCs, BiTEs, chimeric antigen receptor T cell therapies, and other modalities.